Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 10:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 700 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Janssen Research & Development, LLC Clear all
Completed No phase listed Observational Accepts healthy volunteers

Study to Estimate How Common it is to Have Genetic Variants Associated With NAFLD

NCT04494360
View directory record Official record
Conditions
Healthy
Interventions
No intervention
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
830 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Hollywood, Florida • Lenexa, Kansas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 7, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers

NCT01463774
View directory record Official record
Conditions
Healthy
Interventions
Treatment A: Canagliflozin tablet, Treatment A: Metformin IR tablets, Treatment B: Canagliflozin/metformin fixed dose combination tablets
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 21, 2012 · Synced Oct 7, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule

NCT02877225
View directory record Official record
Conditions
Healthy
Interventions
Ibrutinib, IMBRUVICA
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 7, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules

NCT02841150
View directory record Official record
Conditions
Healthy
Interventions
IMBRUVICA (Treatment A), Ibrutinib (Treatment B)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 7, 2026, 10:23 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT03628924
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Guselkumab dose 1, Guselkumab dose 2, Guselkumab dose 3, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
Birmingham, Alabama • Largo, Florida • Ocala, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 7, 2026, 10:23 AM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

NCT01109069
View directory record Official record
Conditions
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Well-differentiated Lymphocytic Lymphoma, B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma, Waldenstrom Macroglobulinemia, Burkitt Lymphoma, B-Cell Diffuse Lymphoma
Interventions
PCI-32765
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
16
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 11 more
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Oct 7, 2026, 10:23 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT01988961
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Golimumab
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
15
States / cities
La Jolla, California • National City, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Oct 7, 2026, 10:23 AM EDT
Completed Early Phase 1 Interventional

A Study of Acute Respiratory Infections in Global Outpatient Setting

NCT05148780
View directory record Official record
Conditions
Acute Respiratory Infection
Interventions
Nasal Swab Sample
Diagnostic Test
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Guntersville, Alabama • Mesa, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 7, 2026, 10:23 AM EDT
Completed Phase 1 Interventional

A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT03915379
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions
JNJ-67571244
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
Boston, Massachusetts • Detroit, Michigan • Hackensack, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 7, 2026, 10:23 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

NCT04811560
View directory record Official record
Conditions
Acute Leukemia
Interventions
Bleximenib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
26
States / cities
Duarte, California • Orange, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 7, 2026, 10:23 AM EDT
Recruiting Phase 3 Interventional

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

NCT07577843
View directory record Official record
Conditions
Crohn Disease
Interventions
JNJ-78934804, Guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
20
States / cities
Anaheim, California • Chula Vista, California • Los Alamitos, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 7, 2026, 10:23 AM EDT
Active, not recruiting Phase 2 Interventional

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

NCT06120140
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab IV, Amivantamab SC, Lazertinib, Doxycycline, Minocycline, Clindamycin, Chlorhexidine, Noncomedogenic skin moisturizer, Ruxolitinib, Tacrolimus, Zinc gluconate, Propranolol, Timolol, Clobetasol
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
28
States / cities
Chandler, Arizona • Duarte, California • Fullerton, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 7, 2026, 10:23 AM EDT
Recruiting Phase 3 Interventional

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

NCT07258511
View directory record Official record
Conditions
Multiple Myeloma
Interventions
JNJ-79635322, Teclistamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
42
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 7, 2026, 10:23 AM EDT
Completed Phase 3 Interventional Results available

Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

NCT00887198
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone acetate, Placebo, Prednisone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,088 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
48
States / cities
Birmingham, Alabama • Tucson, Arizona • Bellflower, California + 45 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 7, 2026, 10:23 AM EDT
Recruiting Phase 1 Interventional

A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer

NCT07524855
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
JNJ-101684362 (HLD-0117)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
New Haven, Connecticut • Sarasota, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 7, 2026, 10:23 AM EDT
Withdrawn Phase 1 Interventional

A Study of Guselkumab in Adult Participants With Celiac Disease

NCT04704843
View directory record Official record
Conditions
Celiac Disease
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Lancaster, California • Chesterfield, Michigan • Wyoming, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 7, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of a Fixed Dose Combination of Canagliflozin/Metformin Coadministered With Food

NCT02039258
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CANA/MET XR FDC
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Oct 7, 2026, 10:23 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

NCT02422186
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (New Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
65 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
San Diego, California • New Haven, Connecticut • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 7, 2026, 10:23 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

NCT07266441
View directory record Official record
Conditions
Multiple Myeloma
Interventions
JNJ-79635322
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
30
States / cities
Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 7, 2026, 10:23 AM EDT
Completed No phase listed Observational

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

NCT04132557
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate, Lisdexamfetamine, Atomoxetine, Amphetamine, Dextroamphetamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
430,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 7, 2026, 10:23 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

NCT07149857
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cilta-cel, Cyclophosphamide, Induction therapy, Fludarabine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
San Francisco, California • Tampa, Florida • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 7, 2026, 10:23 AM EDT
Completed Phase 3 Interventional

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

NCT03009981
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, LHRH Analogue, Abiraterone Acetate, Prednisone
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older · Male only
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
69
States / cities
Phoenix, Arizona • Chula Vista, California • Duarte, California + 58 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 7, 2026, 10:23 AM EDT
Completed Phase 3 Interventional Results available

Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.

NCT00488319
View directory record Official record
Conditions
Schizophrenia, Schizophrenic Disorders, Psychotic Disorders, Dementia Praecox
Interventions
Paliperidone ER
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
14
States / cities
Cerritos, California • San Diego, California • Santa Ana, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 7, 2026, 10:23 AM EDT
Completed Phase 1 Interventional

A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms

NCT05444530
View directory record Official record
Conditions
Myeloproliferative Neoplasms
Interventions
VAC85135, Ipilimumab
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Duarte, California • Tampa, Florida • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 7, 2026, 10:23 AM EDT